Navigation Links
Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
Date:8/13/2008

e served as a valuable opportunity for Sinovac to demonstrate its ability to meet the public's needs as we continue to cultivate the public market for our hepatitis A vaccine."

Three Months Ended June 30, 2008

For the second quarter 2008, sales increased 73% to $16.5 million, compared to $9.5 million in the second quarter 2007. The growth was driven by higher sales of Healive(R) and Bilive(R) following the May 12th earthquake. Government orders after the earthquake generated about $4.6 million, which are not expected to recur in future periods. Sales and other amounts, which are reported here in US dollars, were also affected by the strengthening of the Chinese RMB against the US dollar in the last year.

During the second quarter of 2008, Sinovac sold 2.72 million doses of Healive(R), up from 1.75 million doses for the same period of 2007. Higher sales in the second quarter 2008 resulted from Healive promotion campaign targeting the private market and the increased demand following the May 12th earthquake. During the second quarter of 2008, Sinovac sold 180,000 doses of Bilive(R) compared to sales returns of 13,000 doses in the comparative period.

Gross profit for second quarter 2008 was $13.9 million, with a gross margin of 84.0%, compared to $8.2 million and 86.5%, respectively, for the same period of 2007.

Total operating expenses for the second quarter 2008 increased to $6.9 million, compared to $3.6 million in the same period 2007. Selling, general and administrative expenses for second quarter of 2008 were $6.0 million, compared to $3.5 million in the same period of 2007. The year-over-year increase in SG&A expenses was in line with the increased sales. SG&A expenses as a percentage represented 36.5% of revenues in the second quarter of 2008, compared to 36.3% in the same period in the prior year.

Gross expenditures on research and development expenses for the second quarter of 2008 were $794,000 compared to $322,000 i
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
2. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
3. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
4. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
5. Sinovac Biotech Holds Annual General Meeting
6. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Announces Adjournment of Annual General Meeting
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Sinovac Closes $9.75 Million Private Placement
11. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative ... information about dual arch impressions on its dental blog. ... the blog entry serves up a list of tips to ... demonstration by Dr. David Little as he crafts a porcelain ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
... Burrill & Company Collaborating on Strategic Next Steps ... Developer Tower Investments, LLC ("Tower"), and San Francisco-based ... announced a formal partnership with aims of advancing ... and funding related to the "shovel-ready" BioBusiness Park ...
... , - ThromboGenics Reports Pre-Tax Profit ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused on the ... difference to patient care in a number of important therapeutic,areas, ... for the,full year ending December 31, 2008. , ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4ThromboGenics Announces Business Update and 2008 Full Year Results 2ThromboGenics Announces Business Update and 2008 Full Year Results 3ThromboGenics Announces Business Update and 2008 Full Year Results 4ThromboGenics Announces Business Update and 2008 Full Year Results 5ThromboGenics Announces Business Update and 2008 Full Year Results 6
(Date:4/20/2014)... gift of germsgerms that help to kick-start the ... off infection, may paradoxically interrupt a newborn,s own ... to dangerous pathogens. , A new animal ... of Philadelphia (CHOP) sheds light on immunology in ... crucial role in fostering the rapid production of ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3
... DNA damage resets the cellular circadian clock, suggesting links ... the propensity for cancer. , Their work, reported June ... Science, implies a protective dimension for the biological clock ... a sweeping role in the rhythms and activities of ...
... Scientists from The University of Tokyo announce today that gibbons, ... not carry a major obesity gene that is present in ... is due to a genetic mis-shuffling event that occurred approximately ... the April issue of the scientific journal Genome Research ...
... containing platinum, Virginia Commonwealth University Massey Cancer Center researchers have ... in HIV and cancer. , The findings may help researchers ... targeting proteins known as zinc fingers. , In the May ... that a zinc finger protein, known as HIV NCp7, can ...
Cached Biology News:Novel connection found between biological clock and cancer 2Major obesity gene is 'lost in the shuffle' 2New protein target may advance design of HIV and cancer drugs 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... Perm/Wash Buffer I can be used in ... to permeabilize cells and to serve as ... Because saponin-mediated cell permeabilization is a reversible ... cells in the presence of saponin during ...
Biology Products: